Third View Private Wealth LLC Buys Shares of Illumina, Inc.

The investment firm acquired a new stake in the life sciences company during the fourth quarter.

Apr. 14, 2026 at 10:51am

Got story updates? Submit your updates here. ›

An extreme close-up of complex, highly engineered mechanical and electronic components in shades of silver, black, and blue, conveying the advanced nature of Illumina's DNA sequencing systems.Third View Private Wealth's investment in Illumina signals confidence in the life sciences company's cutting-edge genomic analysis technology.San Diego Today

Third View Private Wealth LLC, an investment management firm, bought a new stake of 16,207 shares in Illumina, Inc. (NASDAQ:ILMN) during the fourth quarter of 2025, according to a filing with the Securities and Exchange Commission. The new stake was valued at approximately $2,126,000.

Why it matters

Illumina is a leading global provider of DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. The company's products are used by academic institutions, government laboratories, and pharmaceutical, biotechnology, and consumer genomics companies around the world. Third View Private Wealth's investment in Illumina signals confidence in the company's long-term growth prospects.

The details

According to the SEC filing, Third View Private Wealth LLC acquired the 16,207 shares of Illumina during the fourth quarter of 2025. The investment firm did not previously own any shares of Illumina. The new stake represents a small but meaningful position in the life sciences company for Third View Private Wealth.

  • Third View Private Wealth LLC acquired the Illumina shares in the fourth quarter of 2025.
  • The SEC filing disclosing the investment was made on April 14, 2026.

The players

Third View Private Wealth LLC

An investment management firm that bought a new stake in Illumina, Inc. during the fourth quarter of 2025.

Illumina, Inc.

A global life sciences company that develops, manufactures, and markets integrated systems for the analysis of genetic variation and function.

Got photos? Submit your photos here. ›

The takeaway

Third View Private Wealth's investment in Illumina reflects the firm's confidence in the life sciences company's long-term growth potential. As a leading provider of DNA sequencing and genomic analysis technologies, Illumina is well-positioned to benefit from the increasing adoption of genetic testing and personalized medicine across the research, clinical, and consumer markets.